“Starting next year, American drug prices will come down fast and furious and will soon be the lowest in the developed world, ...

Trump announced new agreements with major drugmakers to lower prescription costs and boost U.S. pharmaceutical investment.

Though individual terms were not disclosed, the administration has now negotiated lower drug prices with 14 companies since ...

Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an agreement with the U.S. government to provide Eliquis ® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for ...

This initiative marks among the BMS Foundation’s first grants in India to increase access to screening and build capacity to ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

Bristol Myers Squibb BMY recently announced that it will continue the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease. The decision to continue the study follows a ...

Shares of Bristol Myers Squibb BMY gained 5.62% after the company announced the continuation of the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease. The news ...

FRANKFURT, Nov 3 (Reuters) - Germany's BioNTech (22UAy.DE), opens new tab on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb (BMY.N), ...

Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...

Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis ® (apixaban) and Sotyktu ® ...